AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01713777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Generic A
Study NCT01713777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine generic B
Study NCT03181516 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis BB-12
Description: Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
Study NCT03181516 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Yogurt without Bifidobacterium animalis subsp. lactis BB-12
Study NCT03734198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be given at the fixed dose of 420 mg daily for the duration of treatment.
Study NCT03734198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be started 28 days after beginning of ibrutinib and will be administered at the standard dose of 16 mg/kg (divided over two days for the first infusion), then 16 mg/kg for the following infusions, weekly for 2 months, then every other week for 4 months and then once a month until progression or intolerance.
Study NCT01947504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education and support intervention
Study NCT01242904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimodal solution
Description: 200 mL of 30% glucose infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
Study NCT01242904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: icodextrin
Description: 200 mL of icodextrin infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
Study NCT04176796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stratified Transplant Survival
Description: The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]
Study NCT01584050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-5-methyltetrahydrofolate (Metafolin ®)
Description: dosage: 1000 μg, frequency: once daily, duration: 12 weeks
Study NCT01584050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: folic acid
Description: dosage: 1000 μg, frequency: once daily, duration: 12 weeks
Study NCT01584050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: frequency: once daily, duration: 12 weeks
Study NCT00216073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 825 mg/m2 po bid, days 1-14
Study NCT00216073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 100 mg/m2 IV, day 1
Study NCT00216073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 6mg/kg IV, day 1. 8 mg/kg loading dose given in cycle 1 for patients without previous trastuzumab therapy only.
Study NCT02932397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous dose of 0.5 mg/kg of propofol
Study NCT02932397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous dose of 0.05 mL/kg of saline solution
Study NCT04465175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Second dose magnesium sulphate infusion over one hour
Study NCT04465175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (2.5 ml/kg) infusion over one hour
Study NCT00518011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg po daily
Study NCT00518011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: As prescribed
Study NCT00518011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: As prescribed
Study NCT04560504 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Leisure activities
Study NCT04560504 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oculomotor Training Group
Description: Eye movement training
Study NCT03065465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Over-the-scope hemoclipping device
Description: A endoscopic entrapment of tissue for control of bleeding or other applications.
Study NCT03065465 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard endoscopic treatment
Description: Standard therapy includes injection of dilute epinephrine, thermal coagulation with multipolar electrocautery (MPEC) probe, and/or hemoclips.
Study NCT01331148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 10,000 IU/caplet, patients receiving 240,000 IU to 600,000 IU cumulative Vitamin D dose based on weight.
Study NCT01331148 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo with daily calcium/Vitamin D soft chews
Study NCT03175224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-101 Oral Capsules
Description: Subjects will receive APL-101 capsules BID for oral administration.
Study NCT02415634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RECAP
Description: Patients will receive an information pack at ICU discharge called the RECAP. This pack will include~* Part 1: A critical care discharge summary (UCCDIP) (Bench and Day, 2012)~* Part 2: A rehabilitation goal setting care plan~* Part 3: A patient communication forum~* Part 4: Useful supports and contact information~* Part 5: Tailored exercise programme~The patient will have a consultation with the ICU physiotherapist before ICU discharge once weekly thereafter for 3 weeks . The focus of the session will be to discuss goal attainment and associated challenges.~The ICU therapist will meet once weekly with the patient's primary physiotherapist to provide clinical support if necessary, in determining the patient's needs post critical care.
Study NCT02415634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants allocated to the control group will receive standard physiotherapy intervention post ICU discharge
Study NCT02189200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oat bran - 40g
Description: oat bran - 40g per day
Study NCT04414384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal Binder
Description: Abdominal Binder placement
Study NCT04414384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Step Counter
Description: step counter to track steps
Study NCT02189200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: refined rice flour- 40g
Description: refined rice flour - 40g per day
Study NCT01876082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAZOPANIB treatment
Description: Pazopanib~* 800 mg per day~* oral administration~* at least 1 hour before or 2 hours after a meal,~* until disease progression or for 12 months maximum
Study NCT01876082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Vinblastine and Methotrexate
Description: Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
Study NCT03231423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drainage
Description: Using drain after operation
Study NCT01736527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LE Gel
Description: Single drop of LE Gel 0.5% administered to the study eye on visit 2
Study NCT03879135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVWF
Description: Recombinant von Willebrand factor
Study NCT04414384 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Step Counter
Description: step counter to track steps
Study NCT00947297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPN-100
Description: HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4 mL) delivers equivalent of PBA that 40 tablets of NaPBA do.
Study NCT03879135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIII
Description: Recombinant Factor VIII
Study NCT00232245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil
Study NCT01407107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 0.2 MG/HR
Description: 0.2mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr).
Study NCT01407107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 0.4 MG/HR
Description: 0.4mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr) if this is well tolerated a higher dose patch (0.4mg/hr) will be used for the next 3 patients.
Study NCT01407107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 0.6 MG/HR
Description: 0.6mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr) if this is well tolerated a higher dose patch (0.4mg/hr) will be used for the next 3 patients and if this is well tolerated an even higher dose patch (0.6mg/hr) will be used.
Study NCT00836238 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: Physical Function and Symptom Assessment Interviews
Study NCT00836238 — intervention group
Intervention type: OTHER
Intervention: Physical Function Tests
Description: 3 physical function tests.
Study NCT01248130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acid
Description: Children with Autism Spectrum Disorders will be randomized to receive either 1500mg (3 capsules) omega-3 fatty acids or placebo. Each 500mg capsule contains 350mg EPA and 50mg DHA. Omega-3 fatty acids dosing will be on a forced titration schedule to 3 capsules per day. All subjects will start with 1 capsule per day with an increase to 3 capsules per day by week 2. Subjects will be maintained at 3 capsules per day thereafter until the end of the trial (completion/discontinuation). During the 12 weeks of the study period, participants will be evaluated at weekly intervals during the first three weeks of the trial (baseline, weeks 1-3) and tri-weekly thereafter till the end of the trial (weeks 6, 9 and 12). At each visit, measures of safety and effectiveness will be administered and subjects will be evaluated for response and side effects to the treatment. Study medications will be prescribed under double blind conditions.
Study NCT01248130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 Fatty Acid
Description: Children with Autism Spectrum Disorders will be randomized to receive either 1500mg (3 capsules) omega-3 fatty acids or placebo. Each 500mg capsule contains 350mg EPA and 50mg DHA. Omega-3 fatty acids dosing will be on a forced titration schedule to 3 capsules per day. All subjects will start with 1 capsule per day with an increase to 3 capsules per day by week 2. Subjects will be maintained at 3 capsules per day thereafter until the end of the trial (completion/discontinuation). During the 12 weeks of the study period, participants will be evaluated at weekly intervals during the first three weeks of the trial (baseline, weeks 1-3) and tri-weekly thereafter till the end of the trial (weeks 6, 9 and 12). At each visit, measures of safety and effectiveness will be administered and subjects will be evaluated for response and side effects to the treatment. Study medications will be prescribed under double blind conditions.
Study NCT04645342 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baylis Versacross RF wire
Description: Baylis Versacross radiofrequency wire is used for transseptal puncture during cardiac ablation procedure.
Study NCT04645342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baylis RF needle
Description: Baylis radiofrequency needle is used for transseptal puncture during cardiac ablation procedure.
Study NCT01757873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z160
Study NCT01757873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03427827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab is an antibody targeting PD-1 developed by Jiangsu Hengrui Medicine, China.
Study NCT01410565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apaziquone
Description: Apaziquone 4 mg in 40 mL diluent
Study NCT01410565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Double Blind Phase
Study NCT05097066 — intervention group
Intervention type: PROCEDURE
Intervention: Neurosurgical procedure
Description: Any neurosurgical procedure in the National Neurosurgical Audit Programme (NNAP) Coding Framework of neurosurgical procedures.
Study NCT01940276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Study NCT01940276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT01598740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLP
Description: Oral administration
Study NCT01598740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: oral administration
Study NCT04060979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Nitric Oxide given intermittently via inhalation
Study NCT04060979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Supportive treatment
Description: Standard Supportive treatment (including oxygen)
Study NCT04060979 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Supportive treatment
Description: Standard Supportive treatment (including oxygen)
Study NCT03587740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: T-DM1 is an antibody-drug conjugate; it is made up of an antibody (trastuzumab) linked to a cytotoxic drug, DM1 (chemotherapy). T-DM1 functions as a targeted cancer therapy because it targets HER2-positive breast cancer cells directly, limiting exposure of the rest of the body to chemotherapy.
Study NCT03120065 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Dose Monitoring (MEMS)
Description: The MEMS cap is an electronic bottle cap that records the time and date of a bottle being opened. The research personnel will extract the timing of the MEMS bottle opening events for adherence analysis.
Study NCT06363084 — intervention group
Intervention type: DRUG
Intervention: Nimotuzumab
Description: Nimotuzumab (400mg) was given weekly
Study NCT00864474 — intervention group
Intervention type: DRUG
Intervention: CELSENTRI® Tablets
Description: CELSENTRI ® Tablets 150mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage is 300 mg twice daily. Maraviroc must be used in combination with other anti-HIV drugs. The dosage may be adjusted according to co-administered medical products. Maraviroc can be taken with or without food.
Study NCT01945385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video intervention
Description: Brief 7 minute video of physician describing LARC methods followed by two patient testimonials about their own postabortal LARC experience.
Study NCT04666870 — intervention group
Intervention type: OTHER
Intervention: myopia or not myopia
Description: visual acuity, IOL master biometry, the anterior segment with slit lamp, dilated fundus examination and refraction.
Study NCT02804503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie Labels
Description: Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
Study NCT02804503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Labels
Description: Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
Study NCT02804503 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Labels
Description: Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
Study NCT02851108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: 50 patients will receive methylene blue
Study NCT02851108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: 50 patients will receive primaquine
Study NCT00008346 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Full Field Digital Mammography
Description: Radiologic test to screen women for Breast cancer using digital detectors
Study NCT00008346 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Screen Film Mammography
Description: Radiologic test to screen women for Breast cancer using plain film detectors a resolution screen
Study NCT04524403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorlilant
Description: Miricorilant 600 mg (4 X 150 mg) for once-daily for oral dosing
Study NCT04524403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorlilant
Description: Miricorilant 900 mg (6 X 150 mg) for once-daily for oral dosing
Study NCT04524403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for once-daily oral dosing
Study NCT03063359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl + Oral Placebo
Description: Administration of intranasal fentanyl (1.5µg/kg) and Oral placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
Study NCT03063359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Morphine + Intranasal Placebo
Description: Administration of oral morphine (0,4mg/kg) and intranasal placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
Study NCT00283660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 mg zinc oxide
Description: 10 mg zinc oxide
Study NCT00283660 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill taken five days a week for six months.
Study NCT03375346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.
Study NCT03375346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees
Study NCT03375346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees
Study NCT03905551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold Dialysis
Description: Dialysate temperature reduced to 35oC for a period of 7 months.
Study NCT03905551 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Typical Dialysis
Description: Dialysate temperature is set at 37oC for a period of 7 months
Study NCT00029107 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: anti-CD20 monoclonal antibody
Study NCT04208165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided nerve block PVB
Description: Thoracic paravertebral block guided by ultrasound device which allows visualizing the surrounding anatomy and placement of the needle at the target location in real time.
Study NCT03905551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic Intradialytic exercise training
Study NCT03905551 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Aerobic Intradialytic exercise training
Study NCT04208165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided nerve block TAB
Description: Transverse abdominis plane block guided by ultrasound device which allows visualizing the surrounding anatomy and placement of the needle at the target location in real time.
Study NCT05937230 — intervention group
Intervention type: DEVICE
Intervention: Drug-coated balloon
Description: Paclitaxel is a pharmacologically active substance for anti-neointima.
Study NCT05937230 — intervention group
Intervention type: DEVICE
Intervention: Drug-eluting stents
Description: Drug-eluting stent is composed of a metal stent, primer, and drug coating.
Study NCT02776215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: Melatonin receptor agonist